Background: Molecular testing of the deceased (Molecular Autopsy) is an overlooked area in the United States healthcare system and is not covered by medical insurance, leading to ineffective care for surviving families of thousands of sudden unexpected natural deaths each year. We demonstrated the precision management of surviving family members through the discovery of a novel de novo pathogenic variant in a decedent.
Introduction
Medical genetics and genomic testing is emerging onto the center stage in human health, including carrier screening, preimplantation genetic diagnosis, non-invasive prenatal screening, newborn screening, and diagnosis of common or rare heritable conditions. However, the current healthcare system in the United States lacks proper policy and procedures to support some essential medical genetics services. One of the overlooked areas is postmortem genetic testing of decedents who died naturally, suddenly, and unexpectedly at young ages (molecular autopsy). The value of molecular autopsy in the determination of underlying natural causes of death, and the subsequently improved healthcare of surviving family members has been shown in numerous case reports [1, 2, 3] and cohort studies [4, 5, 6] . However, primarily due to lack of coverage from medical insurance, genetic testing of the deceased is not routinely performed in most of the United States, as it is in our Office in the City of New York, leaving thousands of cases unsolved each year and at-risk family members on the hook. This leads to costly and ineffective management of surviving families.
In this study, we present the discovery of a novel de novo pathogenic variant in KCNH2, a long QT syndrome gene, in a young decedent who died suddenly and unexpectedly. We demonstrate how molecular autopsy enables effective precision healthcare to surviving family members which can only be achieved through molecular testing of affected decedents.
With the recently published statement of "Considerations in healthcare reform for patients and families with genetic diseases" by the Board of Directors of the American College of Medical Genetics and Genomics [7] , we advocate that molecular autopsy should be included under healthcare coverage in the United States as it directly impacts surviving family members.
Materials and methods

Case presentation and forensic investigation
An 18-year-old Asian female was found dead in her bedroom in New York City by her family. 911 was called and EMS pronounced the death without medical intervention due to rigor mortis.
Bodies of deceased persons are brought to the New York City Office of Chief Medical Examiner (NYC-OCME) because the law requires that the Chief Medical Examiner investigate deaths of persons dying from criminal violence, by accident, by suicide, suddenly when in apparent health, when unattended by a physician, in a correctional facility, or in any suspicious or unusual manner. The medical examiner is responsible for determining the cause and manner of death. OCME forensic investigation of sudden death includes: scene investigation and family interview (by certified physician assistants), complete gross autopsy, detailed cardiac pathology and neuropathology examinations and microscopic evaluation of important organs, toxicological tests, microbiological tests (in infants), metabolic screening tests (in infants), and medical record review. After these investigations, if the underlying cause of death remains unclear, or if there is suspicion of channelopathy or cardiomyopathy, molecular analysis of a panel of 95 cardiac arrhythmogenic genes by next-generation sequencing (NGS) will be performed [5] .
Postmortem molecular testing
NYC-OCME's in-house College of American Pathologists (CAP)-accredited Molecular Genetics Laboratory performed the testing. NGS testing and Sanger sequencing methods were reported previously [5, 8] . Nomenclature of Sequence variants follows the Human Genome Variant Society (HGVS) recommendations [9] .
Variant interpretation follows the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG-AMP) guidelines published in 2015 [10] . Genetic results include variant location on human-genome reference (GRCh37/hg19). The Institutional Review Board of the New York City Department of Health and Mental Hygiene approved this study.
Genetic counseling and family study
After postmortem molecular testing was completed, OCME's in-house board-certified genetic counselor provided counseling to the parents and four full-siblings of the decedent, and referred them to the Cardiovascular Genetics Program Inherited Arrhythmias Clinic at NYU School of Medicine for clinical evaluation and targeted variant testing. Informed Consent was obtained from all living family members. Genetic testing of family members was performed through a New York State approved commercial company (Invitae Inc.).
Site-directed mutagenesis
The full-length wild-type human ERG cDNA (hERG or Kv11.1; NP_000229.1; clone #1160) in the pRcCMV vector was a gift from Dr. Minoru Horie (Shiga Medical Center, Shiga, Japan). Site-directed mutagenesis, to generate hERG-DQ1068, was performed by Genscript (Piscataway, NJ, USA).
Cell culture
COS-7 or HEK-293 cells were grown in Eagle's Modified Essential Medium (EMEM) (Thermo Fisher Scientific, Waltham, MA), supplemented with heatinactivated 10% Fetal Bovine Serum (FBS) and penicillin (100 IU/mL) and streptomycin (100 mg/mL). Cells were grown in 35 mm culture plates and, unless stated otherwise, transfected at 70e80% confluence using Lipofectamine 2000 reagent (Life Technologies, Carlsbad, CA) with wild-type hERG, hERG-DQ1068, or wild-type hERG plus hERG-DQ1068 cDNAs. In each reaction, 0.1 mg of a GFP plasmid was included to allow visualization of successfully transfected cells by fluorescence microscopy. Patch clamping was performed 48 hours after transfection.
Whole-cell patch-clamp recordings
Membrane current were recorded in the whole-cell configuration at room temperature with Axopatch 200B (Molecular Devices, San Jose, CA), low-pass filtered with 8-pole Bessel filter (-3 dB @ 1 Hz), digitized (3 kHz; DigiData 1550 A, Axon Instruments) and recorded using pClamp v10.5 software (Molecular Devices). Patch electrodes were manufactured using borosilicate glass (1.5 mm OD; World Precision Instruments, Sarasota, FL) and had tip resistances of 2e4 MU when filled with (in mmol/L): 110 KCl, 1 MgCl 2 , 1 EGTA, 10 HEPES, 2 MgATP and pH 7.2, adjusted with KOH. The bath solution consisted of (in mmol/L): 137 NaCl, 5.4 KCl, 1.8 CaCl 2 , 0.5 MgCl 2 , and 10 HEPES, with pH 7.4 adjusted with NaOH. Data were not corrected for the liquid junction potential. The whole-cell capacitance and series resistance were compensated to levels greater than 80%. Currents were corrected for cell size by dividing by the cell capacitance and expressing as pA/pF. 
Western blotting
Surface biotinylation assay
Data analysis
Patch clamp data were analyzed using pClamp 10.5 software and plotted using SigmaPlot software (Systat Software Inc, San Jose, CA). All averaged data are expressed as mean AE SEM. Statistical comparisons were performed using Student's t-tests, and statistical significance was assumed when p < 0.05.
Results
Cause of death determination through forensic examinations
The results of comprehensive forensic studies are summarized in Collectively, the results from comprehensive forensic studies, medical records review and molecular testing support that the cause of death of the 18-year-old decedent was cardiac arrhythmia due to long QT syndrome caused by the pathogenic variant in the KCNH2 gene.
Family study revealed the novel nonsense variant in KCNH2 arose de novo
Baseline EKG of the parents and the four siblings were normal and none exhibited prolonged QT (Fig. 1C) . Targeted testing for the two variants found in the decedent showed that neither parents nor the four siblings in the family harbored the pathogenic variant p.Gln1068Ter in KCNH2; therefore, the variant most likely arose de novo (nonpaternity is denied, but paternity test was not performed). The novel VUS in CACNA2D1 was identified in the mother and one of the siblings who are both asymptomatic with negative EKG. Upon examining 200 bp sequences surrounding the variant site (Fig. 1D) , no CpG islands were found (http://www.bioinformatics.org/sms2/cpg_islands.html) and the variant G to A change is not part of the CpG dinucleotides.
In vitro functional characterization of the novel de novo nonsense variant in KCNH2
To understand the mechanism of pathogenicity, we performed functional studies for the novel de novo KCNH2 variant. The gene product of KCNH2 is a K þ channel asubunit named human ERG (hERG), which we shall use here.
hERG-DQ1068 decreases the current density and negatively shifts the activation voltage threshold
We have introduced a nucleotide change in full-length human ERG (hERG) cDNA with site-directed mutagenesis to generate the hERG-DQ1068 cDNA construct.
Wild-type (WT) hERG or hERG-DQ1068 were expressed in COS-7 cells and whole-cell currents were recorded using standard patch clamp methods. No significant currents were recorded in untransfected COS-7 cells (data not shown). In contrast, transfected COS-7 cells exhibited prototypical outward currents during depolarizing pulses. The currents measured at the end of the depolarizing test pulses, corrected for cell capacitance, were plotted as a function of the test potential and exhibited functional outward rectification, which is a typical feature of hERG currents (Fig. 2) . The current density of hERG-DQ1068 was significantly smaller compared to wild-type for voltages beyond 0 mV. During the repolarization step to -50 mV, large decaying deactivation tail currents were observed ( Fig. 2A, B) . The voltagedependence of tail current densities was sigmoidal, and significantly smaller for hERG-DQ1068 when compared to wild-type (Fig. 2C ). Steady-state activation curves were constructed by normalizing the tail currents to the largest measured tail current (Fig. 2D) , which revealed that the hERG-DQ1068 activated at more negative voltages compared to wild-type. The voltage for half-maximal activation was 4.1 AE 1.07 mV (n ¼ 7) and -10.5 AE 0.44 mV (n ¼ 7; p < 0.05) respectively for wild-type and hERG-DQ1068. To determine whether DQ1068 affects the hERG channel independent of activation gating properties, we measured the fullactivated current-voltage relationship ( Fig. 2E and F ). Channels were fully opened by clamping to þ60 mV, followed by repolarization to various test voltages. The peak amplitude of the tail current, plotted as a function of the test voltage, exhibited inward rectification and showed that the reversal potential of hERG-DQ1068 was similar to wild-type. The fully-activated current was decreased at both positive and negative voltages, suggesting that the number of surface channels is decreased by DQ1068.
Reduced surface expression of hERG-DQ1068 channels
We used biochemical approaches to directly measure hERG surface expression. In an initial experiment, HEK-293 cells were transfected with 0.5 mg of WT or DQ1068 hERG cDNAs. Western blotting of cell lysates revealed an endogenous 135 kDa band in untransfected cells, with the appearance of a 150 kDa band in WT transfected cells. The 150 kDa band represents a mature form of the protein since it was Endo-H resistant, but sensitive to PNGase F (Fig. 3A) . As expected, the Endo-H resistant band of DQ1068 hERG was slightly smaller in size (due to the C-terminal truncation) and appeared a less intense than WT, suggestive of a trafficking defect. Curiously, hERG-DQ1068 also migrated at a molecular size of w120 kDa, which is specific since it is not present in untransfected cells. The identity of this 120 kDa band is unknown and it may be a proteolytic cleavage fragment. To Membrane currents were elicited by a 1 s depolarizing pulse to þ60 mV repeated at 0.05 Hz, followed by variable 4 s test pulses between -100 mV and þ40 mV, with 10 mV increments, to a final step to -80 mV.
(F) Maximal tail current amplitudes during the variable test pulses were plotted as a function of the test pulse potential. Data points represent mean AE SEM. *p < 0.05 with Student's t-test.
better assess changes in surface expression, we performed surface biotinylation assays with HEK-293 cells transfected with 2 mg of the cDNAs, to increase the ratio of overexpressed/endogenous protein. Indeed, these experiments showed that the surface biotinylated hERG-DQ1068 protein was significantly less than wild-type hERG without alterations in total expression ( Fig. 3B and C) . This experiment demonstrates that DQ1068 hERG causes a trafficking defect, without affecting protein stability or degradation. wild-type hERG (n ¼ 3) or hERG-DQ1068 (n ¼ 3). p < 0.05 with a Student's t-test.
hERG-DQ1068 accelerates gating kinetics
We next studied the effects of DQ1068 on the time course of the activation process (opening of the activation gates) by using an "envelope of tails" method. The amplitude of the tail current during repolarization from a conditioning voltage at 20 mV (which gradually opens the activation gates) to -100 mV is directly proportional to the number of open activation gates at the end of the preceding depolarizing step.
The time course of activation was determined by plotting the tail current amplitude as a function of the duration of preceding depolarization step ( Fig. 4A and B) . Subjecting these data points to curve fitting with a single exponential function shows that hERG-DQ1068 activated with a time constant of 82 AE 5.3 ms (n ¼ 6), which was significantly more rapid than wild-type (144 AE 8.2 ms, n ¼ 6, p < 0.05). Deactivation kinetics (re-closing of the activation gates upon repolarization) was obtained by curve fitting of the tail currents in Fig. 4C to a sum of two exponential functions.
Deactivation was strongly voltage dependent, with the time constants of both the fast (Fig. 4D) and slow (Fig. 4E) components of deactivation increasing with membrane depolarization. Both fast and slow components of deactivation occurred more rapidly for hERG-DQ1068 compared to wild-type ( Fig. 4E and D) .
Effects of DQ1068 on inactivation properties
We next performed experiments to determine whether the DQ1068 C-terminal truncation affects inactivation properties of the channel by examining the behavior of the inactivation gate at steady-state (Fig. 5A) . hERG channels are unique in that inactivation occurs much more rapidly than activation. After clamping to a positive 
Diminished cumulative activation of hERG-DQ1068
Some of the effects of hERG-DQ1068 are consistent with a loss-of-function phenotype, such as the reduced current density, reduced surface expression and accelerated deactivation. Other effects, however, are consistent with a gain-of-function phenotype, including the negative voltage shift of steady-state activation curve, the positive shift of the steady-state inactivation curve, and accelerated activation. To resolve these apparent contradictory phenotypes, we assessed cumulative activation using a rapid pacing protocol, which demonstrated that wild-type hERG progressively increases over time as more channels enter the activated state (Fig. 6) . The hERG-DQ1068 channel, in contrast, completely lacked cumulative activation, demonstrating that a loss-of-function predominates, particularly at rapid heart rates.
WT failed to rescue hERG-DQ1068 in the heterozygous state
To simulate the heterozygous state in the decedent, experiments were performed with COS-7 cells co-transfected with wild-type and hERG-DQ1068 cDNAs.
Transfection 1 mg WT hERG cDNA alone led to a current amplitude that was w30 pA/pF at -40 mV, whereas transfection with 0.5 mg WT hERG cDNA led to a current that was w50% smaller (not shown). As expected, the hERG-DQ1068 current density was significantly smaller relative to wild-type (Fig. 7A, B and C). Co-transfecting cells with 0.5 mg each of wild-type WT and DQ1068 did not further reduce current amplitude This occurred in the absence of unexpected changes in protein levels (Fig. 7D ). These data demonstrate haploinsufficiency of the heterozygous state. 
Variant classification using 2015 ACMG-AMP guidelines
We classified the NP_000229.1:p.Gln1068Ter variant based on 2015 ACMG-AMP evidence-weighted sequence variant guidelines:
PVS1 -Predicated null variant in a gene where loss-of-function is a known mechanism of disease. Haploinsufficiency score for KCNH2 gene is 3 in ClinGen.
(https://www.ncbi.nlm.nih.gov/projects/dbvar/clingen/clingen_gene.cgi? sym¼KCNH2&subject). The p.Gln1068Ter variant is predicted to cause a replacement of the amino acid glutamine with a premature stop codon at position 1068 of the KCNH2 gene encoded protein (total 1159 amino acids).
PS3 -Well-established functional study showed a deleterious effect. PM6 -This variant is a de novo (without paternity confirmation).
PP4 -This variant is consistent with the decedent's ante-mortem history of prolonged QT interval on electrocardiogram.
In summary, evidence for classifying the NP_000229.1:p.Gln1068Ter variant include one very strong evidence (PVS1), one strong evidence (PS3), two moderate evidence (PM2 and PM6) and one supporting evidence (PP4); therefore, this variant is classified as pathogenic.
Effective precision healthcare for family members through molecular autopsy
From the perspectives of quality, cost and time effectiveness, we compared the healthcare for family members with (Fig. 8A ) or without molecular autopsy (Fig. 8B ) using a three-generation family model consisting of parents, five siblings and a grandchild where one of the siblings died suddenly and unexpectedly of an undetermined natural cause.
When molecular autopsy is performed (Fig. 8A) Genotype-phenotype evaluation of the family members would also be valuable to understand a VUS found in the decedent. This approach leads to cost and time effective precision healthcare of the family members.
When molecular autopsy is not performed (Fig. 8B) , the presence of a P/LP or VUS, its status as de novo or inherited, or its relationship to the cause of death would be entirely unknown. The family would need to be evaluated and managed due to a positive family history of sudden death, which would entail life-long yearly screening in the form of EKGs and echocardiograms, as well as a diagnostic odyssey of exhaustive genetic testing for all family members.
In the scenario where a P/LP variant is de novo and only present in the decedent, no genetic testing (not even whole genome testing) of the surviving family members would yield a meaningful result and they would have to be followed indefinitely. A possible alternative scenario is if a VUS is found in family members, tested in the absence of any phenotype and only because whole-exome study per person [15] , and yearly clinical evaluation ($300) with EKG ($50) and Echo ($1500) per person and any future children for the remainder of their lives [13, 14] . The total cost of care could easily get into hundreds of thousands of US dollars for the family over time.
Discussion
This study has two important messages: 1) molecular autopsy enabled an accurate determination of the cause of death for the 18-year-old woman who died suddenly and unexpectedly; and 2) molecular autopsy enabled cost-effective and quality healthcare for the surviving first-degree family members (a total of six people in this case). As no one carried the de novo pathogenic variant, there is no risk for recurrent sudden death from the same condition, no need for additional extensive genome testing or yearly follow-up for any of them, and more importantly, no chance of being over treated due to a suspicious VUS. This result will also impact future generations.
De novo variants are increasingly recognized as important causes of health conditions as the field of human genetics shifts from positional mapping of disease loci in large pedigrees with multiple affected members to NGS testing of affected and parents (trio-based) [16] . As such, de novo variants are now well appreciated in severe early-onset disease, even though it is less documented in late-onset diseases, largely due to lack of parental samples for older patients. Recent clinical exome sequencing studies have shown that 60e75% of all sporadic cases that received a molecular diagnosis could be explained by de novo mutations [17, 18] . The majority of pathogenic de novo mutations manifest in a dominant manner. De novo variants have also been reported in diseases underlying the cause of sudden expected natural deaths, such as cardiac channelopathy [19] , cardiomyopathy [20] , epilepsy [21] , etc.
For example, de novo variants can explain up to 20% of cases of non-familial Brugada syndrome [22] . In a published cohort of 28 sudden death in the young (SDY) [23] , about 50% of pathogenic variants resulted from de novo alterations. Besides de novo variants, the identification of an inherited variant would also enable targeted cascade variant testing in family members and genotype-phenotype correlation through clinical evaluations as we have previously reported [1, 2, 3] .
Our electrophysiological characterization of the KCNH2 variant introduced into transfected cells found that it resulted in loss-of function (reduced current density, reduced surface expression and accelerated deactivation) hallmarks, which can't be rescued by wild type, a finding consistent with a haploinsufficiency phenotype in the heterozygous state as previously shown in in silico models of cardiac electrophysiology [24] ; the results are also consistent with functional studies for two nonsense KCNH2 variants, p.Q725TER and p.R1014TER [25] , both are upstream of our variant (p.Gln1068Ter). As the identified premature stop codon occurs more than 50 bp upstream of the normal stop codon, it is also possible that there exists the nonsense mediated decay mechanism that we are not tested in this study. A RNAseq analysis of affected heart tissue would be considered for a future study.
Among the loss-of-function variants close to our variant in KCNH2 which have been reported previously, one is the p.Gln1068Thrfs, which was reported as a pathogenic variant in ClinVar without phenotype information [26] ; another is the p.Gln1070Ter which led to miscarriage and intrauterine fetal loss in the homozygous states, although the heterozygote parents only showed borderline long QT [27] . We noticed the decedent in our study had marked QTc prolongation as a heterozygote, for which there may be additional genetic or environmental modifiers at play that are not discovered in this study. Therefore, it would be prudent for the family members to avoid agents (e.g. medications) known to prolong QTc. Among family members, we did not appreciate a difference in QT duration that could distinguish carriers of the CACNA1D variant from non-carriers, so the role of that specific "hit" in influencing QT duration is unlikely or minimal. In addition, other studies have shown nonsense variants leading to a similar QTc interval as we observed, or even a more severe phenotype at younger ages [28, 29] , although the correlation of a specific genotype to a phenotype lacked in cohort-based studies.
Applying molecular autopsy to death investigation has yielded impactful results to families all over the world [5, 23, 30, 31] . Over the past 15 years, our office has become the first and only medical examiner's office in the United States to routinely perform molecular autopsy in sudden unexpected deaths in-house. The forward-thinking leadership in New York City decided to utilize existing resources (lab space, instruments, personnel, etc.) through the largest forensic laboratory in the nation, to build an in-house College of American Pathologists (CAP)-accredited molecular genetics laboratory, and to provide on-site family counseling through board-certified genetic counselor. The National Institute of Justice has also substantially supported the technology expansion to massive parallel sequencing, functional study and genetic counseling through several research grants. We have published our work on testing for thrombophilia [6, 32] and for cardiac arrhythmogenic genes [1, 3, 4, 5] , and we expect to add testing for other inheritable conditions at risks for sudden death, such as epilepsy and aortopathy soon. Joining other studies that described recommendations for molecular autopsy [31, 33] , we have outlined an example of best practice of postmortem diagnosis and effective care for the survival family members in this manuscript. However, molecular autopsy is not routinely being used in sudden unexpected natural deaths investigations in other parts of the United States, primarily due to lack of sustainable funding support and medical coverage, leaving thousands of cases untested and poor clinical care for at-risk family members [23] .
Conclusion
We demonstrated effective precision healthcare of surviving family members (six in this case) through in-depth study of a novel de novo pathogenic variant in the Long QT syndrome type 2 gene KCNH2. As molecular autopsy saves money, time and efforts, and removes psychological stress and anxiety from the healthcare of surviving family members, we advocate a reform of the U.S. healthcare system by including molecular autopsy through the care of the first-degree relatives. "Hic locus est ubi mors gaudet succurrere vitae e this is the place where the dead are pleased to help the living"; we feel strongly that it is our professional duty to advocate for the healthcare coverage of molecular autopsy for the betterment of humanity.
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